Schematic illustration of the new MOF Antibody crystals and their ability to specifically seek out cancer cells to detect them and deliver highly potent drugs with unprecedented precision.
CREDIT: Dr Francesco Carraro and Prof Paolo Falcaro (Co-First and Co-Senior author on the Advanced Materials Paper)
It sounds like the stuff of science fiction: a man-made crystal that can be attached to antibodies and then supercharge them with potent drugs or imaging agents that can seek out diseased cells with the highest precision, resulting in fewer adverse effects for the patient.
However, that is precisely what researchers from the Australian Centre for Blood Diseases at Monash University in collaboration with the TU Graz (Austria) have developed: the world’s first metal-organic framework (MOFs) antibody-drug delivery system that has the potential to fast-track potent new therapies for cancer, cardiovascular and autoimmune diseases.
The in vitro study showed that when MOF antibody crystals bind to their target cancer cells and if exposed to the low pH in the cells, they break down, delivering the drugs directly and solely to the desired area.
The metal-organic framework, a mixture of metal (zinc) and carbonate ions, and a small organic molecule (an imidazole, a colourless solid compound that is soluble in water) not only keeps the payload attached to the antibody but can also acts as a reservoir of personalised therapeutics. This is a benefit with the potential to become a new medical tool to target specific diseases with customised drugs and optimised doses.
The findings are now published in the world-leading journal Advanced Materials.
Co-senior author Professor Christoph Hagemeyer, Head of the NanoBiotechnology Laboratory at the Australian Centre for Blood Diseases, Monash University, says while more funding is needed to take the research into the next phase and to patients, the new method is cheaper, faster and more versatile than anything available currently.
“The method offers the opportunity to personalise treatment and given the precision possible, may eventually change the current dosage needed for patients, resulting in fewer side effects and making treatments cheaper,” said Professor Hagemeyer.
Co-first author Dr Karen Alt, Head of the Nano Theranostics Laboratory at the Australian Centre for Blood Diseases, Monash University, says: “With just 0.01 per cent of chemotherapy currently reaching the cancer tissue, this revolutionary new method can boost the potency of the drugs reaching their target.”
“With over 80 different monoclonal antibodies approved for clinical use, this approach has enormous potential to improve these antibodies for the targeted delivery of diagnostic agents and therapeutic drugs. The goal is that ultimately the clinical translation of this technology will improve the quality of life for patients suffering from serious diseases,” said Dr Alt.
Original Article: Researchers develop a world-first antibody-drug delivery system
More from: Monash University | Graz University of Technology
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Antibody-drug delivery system
- Parenteral Perspectives
Exploring innovations, challenges, and future horizons in parenteral drug delivery.
- Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse® for Advanced Parkinson’s Disease
CINCINNATI and HUNTSVILLE, Alabama, May 15, 2024 (GLOBE NEWSWIRE) -- (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform and Serina ...
- Directing the production of broadly neutralizing antibodies against HIV
Researchers have developed a vaccine that directs the immune system to produce neutralizing antibodies against HIV.
- Advancements in cancer therapy: The revolutionary role of antibody-drug conjugates
The emergence of antibody-drug conjugates (ADCs ... across Sino Biological’s portfolio for precise cancer cell drug delivery, as well as a supporting cast of MMPs, Cathepsins, and uPA enzymes ...
- Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024
Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced two presentations at the 20 th Annual PEGS ...
Go deeper with Google Headlines on:
Antibody-drug delivery system
[google_news title=”” keyword=”antibody-drug delivery system” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Metal-organic framework antibody-drug delivery
- Advancements in cancer therapy: The revolutionary role of antibody-drug conjugates
The emergence of antibody-drug conjugates (ADCs ... across Sino Biological’s portfolio for precise cancer cell drug delivery, as well as a supporting cast of MMPs, Cathepsins, and uPA enzymes ...
- Entering the recognition domain
The host–guest properties of metal–organic frameworks have usually relied ... catalysis and biological applications, including drug delivery 7. As beautifully demonstrated by Li, Zhang and ...
- IDTechEx Forecasts Metal-Organic Frameworks Market to Grow to US$685 Million by 2034
BOSTON, April 25, 2024 /PRNewswire/ -- Metal-organic frameworks (MOFs) are a class of materials with exceptionally high porosity and surface area (up to 7000m 2 /g). The design flexibility and ...
- IDTechEx Release New Global Metal-Organic Frameworks Market Report
IDTechEx Research, a trusted provider of independent market intelligence, announces the availability of a new report, "Metal-Organic Frameworks ... applications (e.g. drug delivery), agricultural ...
- Manufacturing Concepts for Antibody-Drug Conjugates
Recent advances in the coupling of antibodies to potent cytotoxic drugs have resulted in stable delivery platforms with improved pharmacokinetics, which spares patients from debilitating systemic ...
Go deeper with Google Headlines on:
Metal-organic framework antibody-drug delivery
[google_news title=”” keyword=”metal-organic framework antibody-drug delivery” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]